The Criticality Of Excipient Purity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Criticality Of Excipient Purity

Pharmaceutical Technology Europe

George J. Rizzo is Research Team Leader – Health Care, Technical Applications and Product Development at Croda Inc.
Excipient purity is critical in all applications of drug formulation. Typically, the more sensitive or reactive an API, the more critical excipient purity becomes. When evaluating or choosing any excipient, however, purity should always be a priority. Excipient impurities can directly impact the stability of the drug active and its performance, which in turn will lead to poor bioavailability, and affect the end product’s pharmacokinetics and pharmacodynamics. Side effects associated with excipient impurity are breakdown of the API and poor performance, and impurities in even the simplest formulation can lead to a failed end product.

The pharmaceutical industry takes the issue of excipient purity very seriously and must keep up to date with the changes issued by governing bodies that regulate APIs and materials used in drug formulation. The FDA, the US Pharmacopeia, the European Pharmacopeia and the Japanese Pharmacopeia are the main governing bodies and are heavily involved with regards to limits of usage of the excipient per route of entrance into the body for specific applications. These bodies are constantly making improvements to monographs to ensure that patient safety is a first priority.

Improving excipients to ensure purity is a heavily involved process that begins with being aware of what issues are relevant to drug formulators. Once a problem is identified, a corrective plan is established in the research and development laboratories to physically solve and correct the problem at hand. Once a solution has been obtained, the work is then transferred to the commercial side for mass production, which is achieved on the commercial scale by putting in place good process controls and quality systems that ensure high purity material is produced on a consistent basis.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here